Biotech startup Ahammune Biosciences has successfully raised $5 million in its Series A funding round, led by pi Ventures, to accelerate the development of its innovative drug for vitiligo.
- Funding Details: The Series A round raised $5 million (approximately INR 41 crore) with participation from Capital2B, Colossa Ventures, and several existing investors, including Ideaspring Capital and Kotak Alternate Assets.
- Expansion of R&D: The funding will also help expand Ahammune’s patent portfolio and research efforts for other immune-mediated skin diseases, such as eczema, which affects 20% of children in the West.
- Strong Team and IP Portfolio: Founded in 2016 by Dr. Parul Ganju and Dr. Krishnamurthy Natarajan, the startup has an eight-member team, including four PhDs, and has filed 20 patent applications, with seven granted across various countries.
- Market Context: The investment comes as the Indian biotech landscape evolves, supported by initiatives from the Department of Pharmaceuticals to promote innovation in the sector.
Ahammune Biosciences is set to transform the treatment landscape for vitiligo and other skin conditions, offering innovative therapies that tackle essential health issues while minimizing the side effects seen with existing treatments.
